

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **99V**

Lot-specific information  
**Olerup SSP® HLA-C\*02**

Product number:	101.622-12 - including <i>Taq</i> polymerase 101.622-12u - without <i>Taq</i> polymerase
Lot number:	99V
Expiry date:	2016-December-01
Number of tests:	12
Number of wells per test:	31+1
Storage - pre-aliquoted primers:	dark at -20°C
- PCR Master Mix:	-20°C
- Adhesive PCR seals	RT
- Product Insert	RT

**This Product Description is only valid for Lot No. 99V.**

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

**CHANGES COMPARED TO THE PREVIOUS OLERUP SSP®  
HLA-C\*02 LOT (95R)**

The HLA-C\*02 kit is updated for new alleles to enable separation of:

- Confirmed<sup>1</sup> alleles as listed in the IMGT/HLA database
- Polymorphisms in exons outside of the region encoding the peptide binding domain
- Null and Alternatively expressed alleles

A well containing Negative Control primer pairs has been added.

The format of the Product Insert and Worksheet have been changed.

<sup>1</sup>As described in section Uniquely Identified Alleles.

The HLA-C\*02 specificity and interpretation tables have been updated for the HLA-C alleles described since the previous *Olerup SSP®* HLA-C\*02 lot was made (**Lot No. 95R**).

As of lot series V, the Specificity Table is included in the lot-specific Product Insert, and the Interpretation Table is included in the Worksheet.

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **99V**

**Lot-specific information**

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

Well	5'-primer	3'-primer	rationale
4	Added	Added	Primer pair added for the C*02:56 allele.
6	Added	-	5'-primer added for the C*02:64 allele.
13	-	Added	3'-primer added for the C*02:49 allele.
15	-	Added	3'-primer added for the C*02:71 allele.
20	Added	Added	Primer pair added for the C*02:65 allele, 3'-primers added for the C*02:71 and C*02:72 alleles.
21	Added	-	5'-primers added for the C*02:64 and C*02:67Q alleles.
22	Added	Added	Primer pair added for the C*02:56 allele.
23	-	Added	3'-primers added for the C*02:69 and C*02:70 alleles.
25	Added	-	5'-primer added for the C*02:60 allele.
26	-	Added	3'-primer added from well 32.
27	-	Added	3'-primer added from well 32.
28	Added	-	5'-primers added for the C*02:60 and C*02:67 alleles.
32	Removed	Moved	3'-primers moved to wells 26 and 27.

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **99V**

Lot-specific information

Well **32** contains Negative Control primer pairs, that will amplify more than 95% of the *Olerup SSP*® HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.  
The PCR product generated by the positive control primer pair is 430 base pairs.

Length of PCR product	105	200	105	80	75	80	85
<b>5'-primer<sup>1</sup></b>	<b>164</b>	<b>340</b>	<b>440</b>	<b>45</b>	<b>45</b>	<b>43</b>	<b>36</b>
	5'-CAC <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-TAC <sup>3'</sup>
							<b>36</b>
							5'-TAT <sup>3'</sup>
<b>3'-primer<sup>2</sup></b>	<b>231</b>	<b>2<sup>nd</sup> I</b>	<b>507</b>	<b>59</b>	<b>58</b>	<b>57</b>	<b>47</b>
	5'-TgC <sup>3'</sup>	5'-AAA <sup>3'</sup>	5'-TTg <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ACA <sup>3'</sup>
							<b>48</b>
							5'-gCA <sup>3'</sup>
							<b>48</b>
							5'-gCC <sup>3'</sup>
							<b>52</b>
							5'-TgT <sup>3'</sup>
<b>A*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>B*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>C*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>DRB1</b>				<b>+</b>	<b>+</b>		
<b>DRB3</b>				<b>+</b>	<b>+</b>		
<b>DRB5</b>				<b>+</b>			
<b>DQB1</b>					<b>+</b>		
<b>DPB1</b>						<b>+</b>	
<b>DQA1</b>							<b>+</b>

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **99V**

Lot-specific information

## PRODUCT DESCRIPTION

### HLA-C\*02 SSP typing

#### CONTENT

The primer set contains 5'- and 3'-primers for identifying the C\*02:02 to C\*02:81 alleles.

#### PLATE LAYOUT

Each HLA-C\*02 test consists of 32 PCR reactions in a 32 well cut PCR plate.

<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>
<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>	<b>13</b>	<b>14</b>	<b>15</b>	<b>16</b>
<b>17</b>	<b>18</b>	<b>19</b>	<b>20</b>	<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>
<b>25</b>	<b>26</b>	<b>27</b>	<b>28</b>	<b>29</b>	<b>30</b>	<b>31</b>	<b>NC</b>

The 32 well PCR plate is marked with 'HLA-C\*02' in silver/gray ink.

Well No. 1 is marked with the Lot No. '99V'.

Wells 1 to 31 – HLA-C\*02 high resolution primers.

Well 32 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are heat-sealed with a PCR-compatible foil.

**Please note:** When removing each 32 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

#### INTERPRETATION

Due to the sharing of sequence motifs between HLA-C alleles, non-HLA-C\*02 alleles will be amplified by primer mixes 1 to 8, 10, 12 to 14, 16 to 18, 20 to 22, 24, 25, 28 to 30 and 31. In addition, a few HLA-A and HLA-B alleles will be amplified by primer mixes 3 to 5, 12, 16, 19, 20, 22, 25, 28 and 31.

For further details see Specificity Table.

#### UNIQUELY IDENTIFIED ALLELES

All the HLA-C\*02 alleles, i.e. **C\*02:02 to C\*02:81**, recognized by the HLA Nomenclature Committee in April 2014<sup>1,2</sup> will be amplified by the primers in the HLA-C\*02 SSP kit.

The HLA-C\*02 kit enables separation of the confirmed HLA-C\*02 alleles as listed in the IMGT/HLA database. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-C\*02 alleles is listed below.

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

**Lot No.: 99V**

**Lot-specific information**

The HLA-C\*02 kit also enables identification of polymorphisms in exons outside of the region encoding the peptide binding domain and of null and alternatively expressed alleles.

The following HLA-C\*02 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

Alleles	Primer mix	Alleles	Primer mix
C*02:05:02-02:05:03, 02:22	5	C*02:25Q, 02:30	21
C*02:15, 02:21	15	C*02:35, 02:69, 02:70	23
C*02:24, 02:65	20	C*02:37, 02:52N	28

The HLA-C\*02 primer set cannot distinguish the following silent mutations: the C\*02:02:01-02:02:03, 02:02:06-02:02:12 and 02:02:15-02:02:25 alleles, the C\*02:02:05 and 02:02:14 alleles, the C\*02:05:02-02:05:03 alleles or the C\*02:26:01-02:26:03 alleles.

<sup>1</sup>HLA-C alleles listed on the IMGT/HLA web page 2014-April-14, release 3.16.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

<sup>2</sup>Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **99V**

Lot-specific information

**ALLELE CONFIRMATION STATUS**

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
C*02:02:01	Unconfirmed	C*02:05:03	Unconfirmed	<b>C*02:31</b>	<b>Confirmed</b>	C*02:62	Unconfirmed
<b>C*02:02:02:01</b>	<b>Confirmed</b>	<b>C*02:06</b>	<b>Confirmed</b>	<b>C*02:32</b>	<b>Confirmed</b>	C*02:63	Unconfirmed
C*02:02:02:02	Unconfirmed	<b>C*02:07</b>	<b>Confirmed</b>	C*02:33	Unconfirmed	<b>C*02:64</b>	<b>Confirmed</b>
<b>C*02:02:03</b>	<b>Confirmed</b>	C*02:08	Unconfirmed	<b>C*02:34</b>	<b>Confirmed</b>	<b>C*02:65</b>	<b>Confirmed</b>
C*02:02:05	Unconfirmed	C*02:09	Unconfirmed	C*02:35	Unconfirmed	C*02:66	Unconfirmed
C*02:02:06	Unconfirmed	<b>C*02:10</b>	<b>Confirmed</b>	C*02:36	Unconfirmed	<b>C*02:67Q</b>	<b>Confirmed</b>
<b>C*02:02:07</b>	<b>Confirmed</b>	C*02:11	Unconfirmed	<b>C*02:37</b>	<b>Confirmed</b>	C*02:68	Unconfirmed
<b>C*02:02:08</b>	<b>Confirmed</b>	C*02:12	Unconfirmed	<b>C*02:38N</b>	<b>Confirmed</b>	C*02:69	Unconfirmed
<b>C*02:02:09</b>	<b>Confirmed</b>	<b>C*02:13</b>	<b>Confirmed</b>	C*02:39	Unconfirmed	C*02:70	Unconfirmed
C*02:02:10	Unconfirmed	<b>C*02:14</b>	<b>Confirmed</b>	<b>C*02:40</b>	<b>Confirmed</b>	<b>C*02:71</b>	<b>Confirmed</b>
<b>C*02:02:11</b>	<b>Confirmed</b>	C*02:15	Unconfirmed	C*02:42	Unconfirmed	C*02:72	Unconfirmed
<b>C*02:02:12</b>	<b>Confirmed</b>	C*02:16:01	Unconfirmed	C*02:43	Unconfirmed	C*02:73	Unconfirmed
<b>C*02:02:13</b>	<b>Confirmed</b>	<b>C*02:16:02</b>	<b>Confirmed</b>	<b>C*02:44</b>	<b>Confirmed</b>	C*02:74	Unconfirmed
C*02:02:14	Unconfirmed	<b>C*02:17</b>	<b>Confirmed</b>	C*02:45	Unconfirmed	C*02:75	Unconfirmed
C*02:02:15	Unconfirmed	<b>C*02:18</b>	<b>Confirmed</b>	<b>C*02:46</b>	<b>Confirmed</b>	C*02:76	Unconfirmed
<b>C*02:02:16</b>	<b>Confirmed</b>	<b>C*02:19</b>	<b>Confirmed</b>	C*02:47	Unconfirmed	C*02:77	Unconfirmed
C*02:02:17	Unconfirmed	C*02:20	Unconfirmed	C*02:48	Unconfirmed	C*02:78	Unconfirmed
C*02:02:18	Unconfirmed	C*02:21	Unconfirmed	<b>C*02:49</b>	<b>Confirmed</b>	C*02:79	Unconfirmed
C*02:02:19	Unconfirmed	C*02:22	Unconfirmed	C*02:50	Unconfirmed	C*02:80	Unconfirmed
C*02:02:20	Unconfirmed	C*02:23	Unconfirmed	C*02:51	Unconfirmed	C*02:81	Unconfirmed
<b>C*02:02:21</b>	<b>Confirmed</b>	<b>C*02:24</b>	<b>Confirmed</b>	C*02:52N	Unconfirmed		
C*02:02:22	Unconfirmed	<b>C*02:25Q</b>	<b>Confirmed</b>	<b>C*02:53</b>	<b>Confirmed</b>		
C*02:02:23	Unconfirmed	<b>C*02:26:01</b>	<b>Confirmed</b>	C*02:54	Unconfirmed		
<b>C*02:02:24</b>	<b>Confirmed</b>	<b>C*02:26:02</b>	<b>Confirmed</b>	<b>C*02:55</b>	<b>Confirmed</b>		
C*02:02:25	Unconfirmed	<b>C*02:26:03</b>	<b>Confirmed</b>	<b>C*02:56</b>	<b>Confirmed</b>		
C*02:02:26	Unconfirmed	<b>C*02:27:01</b>	<b>Confirmed</b>	C*02:57	Unconfirmed		
C*02:03	Unconfirmed	<b>C*02:27:02</b>	<b>Confirmed</b>	C*02:58	Unconfirmed		
C*02:04	Unconfirmed	C*02:28	Unconfirmed	C*02:59	Unconfirmed		
C*02:05:01	Unconfirmed	C*02:29	Unconfirmed	<b>C*02:60</b>	<b>Confirmed</b>		
<b>C*02:05:02</b>	<b>Confirmed</b>	<b>C*02:30</b>	<b>Confirmed</b>	C*02:61	Unconfirmed		

<sup>1</sup> Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2014-April-14, release 3.16.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

**RESOLUTION IN HOMO- AND HETEROZYGOTES**

Results file with resolution in HLA-C\*02 homo- and heterozygotes is available upon request.

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **99V**

Lot-specific information  
**SPECIFICITY TABLE**

**HLA-C\*02 SSP subtyping**

Specificities and sizes of the PCR products of the 31+1 primer mixes used for HLA-C\*02 SSP subtyping

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA-C*02 alleles <sup>3</sup>	Other amplified HLA Class I alleles <sup>4</sup>
<b>1</b>	250 bp	<b>800 bp</b>	*02:02:01-02:02:03, 02:02:05-02:02:26, 02:04-02:15, 02:17, 02:19-02:31, 02:33-02:40, 02:42-02:71, 02:73-02:81	*01:04, 01:09, 01:21, 04:94:01-04:94:02, 05:08, 05:52, 05:89, 06:02:01:01-06:02:01:03, 06:02:03-06:03:02, 06:07-06:39, 06:41-06:78, 06:80-06:117, 06:119-06:131, 08:27, 08:29, 08:31, 12:02:01-12:08, 12:10:01-12:13, 12:15-12:17, 12:21-12:23, 12:25-12:82, 12:84N, 12:86-12:125, 14:16, 15:74, 16:04:01, 16:29, 16:33, 16:42, 16:55, 16:61, 16:66, 18:03
<b>2<sup>5</sup></b>	95 bp	<b>800 bp</b>	*02:02:01-02:02:03, 02:02:06-02:02:12, 02:02:15-02:02:26, 02:04, 02:05:02-02:05:03, 02:07-02:09, 02:11, 02:13, 02:15, 02:19-02:27:01, 02:28-02:31, 02:34-02:40, 02:42-02:50, 02:52N-02:57, 02:59-02:71, 02:74-02:75, 02:77-02:81	*12:03:17
<b>3<sup>5</sup></b>	100 bp	<b>800 bp</b>	*02:03, 02:16:02, 02:18, 02:31	*03:03:22, 03:04:34, <b>B*27:34</b> , <b>B*35:01:30<sup>w</sup></b> , <b>B*40:02:07</b> , <b>B*40:06:02</b> , <b>B*57:01:16<sup>w</sup></b> , <b>B*57:03:02<sup>w</sup></b>
<b>4<sup>5</sup></b>	135 bp 65 bp	1070 bp	*02:20	<b>B*35:01:30</b> , <b>B*57:01:16</b> , <b>B*57:03:02</b>
<b>5</b>	150 bp 145 bp 240 bp	1070 bp	*02:04 *02:22 *02:05:01-02:05:03, 02:17	*12:115, 14:41 *08:31, <b>B*07:02:07</b> , <b>B*27:05:15</b> *01:10, 06:08, 12:119, 14:25, 16:29, 16:50, 17:21, <b>B*40:243</b>
<b>6</b>	160 bp 210 bp	<b>800 bp</b>	*02:06, 02:47 *02:46, 02:64	*12:15, 15:74
<b>7</b>	130 bp	<b>800 bp</b>	*02:07	*16:10, 16:67
<b>8<sup>5</sup></b>	70 bp 280 bp	1070 bp	*02:08 *02:33	*03:18:02, 03:64:01, 12:03:23, 15:10:02-15:10:03
<b>9</b>	200 bp	1070 bp	*02:02:01-02:02:03, 02:02:05-02:09, 02:11-02:13, 02:15-02:28, 02:30-02:40, 02:42-02:57, 02:59-02:81	

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: <b>99V</b>		Lot-specific information		
<b>10<sup>7</sup></b>	130 bp	1070 bp	*02:02:01-02:02:03, 02:02:05-02:02:12, 02:02:14- 02:02:25, 02:03-02:25Q, 02:27:01-02:38N, 02:40, 02:42-02:44, 02:46-02:81	*04:03:01-04:03:02, 04:06, 04:80, 04:107, 04:147, 04:160, 05:26, 15:11, 16:34
<b>11<sup>5</sup></b>	90 bp 170 bp	<b>800 bp</b>	*02:18, 02:32 *02:09	
<b>12</b>	150 bp	1070 bp	*02:11, 02:14	*04:42, 05:43, 06:05 <sup>w</sup> , 07:02:09, 08:37, 12:16, 15:23, 15:63, 16:21, <b>B*27:84</b>
	230 bp		*02:17	*14:25
<b>13<sup>6</sup></b>	225 bp 265 bp	1070 bp	*02:12, 02:27:01-02:27:02 *02:49, 02:75	*16:34 *04:03:01-04:03:02, 04:06, 04:80, 04:147, 04:160
<b>14<sup>5</sup></b>	80 bp 115 bp	<b>800 bp</b>	*02:13 *02:43	*12:03:17
<b>15</b>	130 bp 190 bp	1070 bp	*02:21 *02:15, 02:71	
<b>16<sup>6,7</sup></b>	250 bp	1070 bp	*02:03, 02:16:01-02:16:02, 02:18	*01:22, 01:35, 04:04:01-04:04:02, 04:06, 04:13, 04:34, 04:58, 04:122, 04:160, 05:11, 05:17, 05:27, 05:68, 05:70, 05:79, 06:04, 06:118, 08:01:01-08:01:15, 08:03:01- 08:04:03, 08:06, 08:08:01-08:11, 08:13-08:14, 08:16:01-08:16:02, 08:20-08:22, 08:24, 08:26N, 08:36N, 08:38-08:42, 08:44, 08:46, 08:50, 08:54, 08:56-08:61, 08:65- 08:66, 08:72:01-08:72:02, 08:78- 08:89N, 08:91, 08:93, 08:95-08:99, 08:101-08:102, 08:104-08:106, 12:14:01-12:14:02, 12:18:01- 12:18:02, 12:20, 12:83, 14:06, 14:15, 14:53, 15:02:01-15:07, 15:09-15:13, 15:15-15:19, 15:21- 15:24, 15:26-15:73, 15:76-15:83, 15:85-15:87, 16:35, 16:40, 16:48, 17:01:01:01-17:16, 17:18-17:24, <b>B*58:02</b>
<b>17<sup>5</sup></b>	110 bp 160 bp	1070 bp	*02:31, 02:43 *02:23	*12:03:17
<b>18</b>	235 bp	<b>800 bp</b>	*02:26:01-02:26:03	*03:07, 03:10, 03:15, 03:29, 03:45, 03:163, 04:16, 04:42, 04:103, 05:01:01:01-05:01:25, 05:01:27, 05:03-05:12, 05:14-05:19, 05:21- 05:25, 05:27-05:29:02, 05:31- 05:77, 05:79-05:102, 06:02:01:01- 06:02:01:03, 06:02:03-06:02:08, 06:02:10-06:02:20, 06:02:22-06:10, 06:12-06:17, 06:19-06:32, 06:34- 06:81, 06:83-06:103, 06:105- 06:118, 06:121-06:124, 06:126- 06:131, 07:07, 07:09, 07:76:01- 07:76:02, 07:315, 07:328, 08:10,



101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
"Instructions for Use" (IFU)

Lot No.: **99V**

Lot-specific information

				12:04:01-12:05, 12:09, 12:21, 12:33, 12:41, 12:60, 12:72, 15:02:01-15:06:03, 15:08-15:10:03, 15:12-15:13, 15:15-15:19, 15:21-15:24, 15:26-15:35, 15:37-15:42, 15:44-15:84Q, 15:86-15:87, 16:02:01-16:02:07, 16:02:09-16:02:12, 16:09, 16:12, 16:19, 16:25, 16:37, 16:46-16:48, 16:60, 16:63, 16:69-16:70, 17:01:01:01-17:01:08, 17:01:10-17:21, 17:23-17:24, 18:01-18:07N
<b>19<sup>5</sup></b>	80 bp	1070 bp	*02:03, 02:28	<b>B*27:34, B*35:01:30<sup>w</sup>, B*40:02:07, B*40:06:02, B*57:01:16<sup>w</sup>, B*57:03:02<sup>w</sup></b>
<b>20<sup>5</sup></b>	50 bp	1070 bp	*02:65	*01:59, 03:130, 03:140, 03:243, 04:114, 05:20, 06:82, 07:49, 07:210, 07:238, 07:247, 12:54, 14:04, 14:64, 15:85, 16:57, <b>A*68:46</b>
	180 bp		*02:24, 02:71	<b>B*07:113, B*08:64, B*40:192</b>
	215 bp		*02:72	<b>B*07:52</b>
<b>21<sup>5</sup></b>	115 bp	1070 bp	*02:30	*15:19
	210 bp		*02:25Q, 02:64, 02:67Q	
<b>22<sup>5</sup></b>	65 bp	1070 bp	*02:56	<b>B*35:01:30, B*57:01:16, B*57:03:02</b>
	110 bp		*02:34	*16:09
<b>23<sup>5</sup></b>	85 bp	1070 bp	*02:70	
	210 bp		*02:29, 02:69	
	390 bp		*02:35	
<b>24</b>	325 bp	1070 bp	*02:06, 02:23, 02:36, 02:68	*01:90, 03:81, 03:175, 03:199, 03:245, 04:108, 06:89, 07:123, 07:173, 07:294, 12:15, 12:113, 15:02:01-15:02:17, 15:02:19-15:03, 15:05:01-15:13, 15:15-15:19, 15:21-15:24, 15:26-15:29, 15:31-15:39, 15:41-15:63, 15:67-15:75, 15:78-15:87, 16:20
<b>25</b>	160 bp	<b>800 bp</b>	*02:19, 02:23	*01:09, 03:21, 03:80, 03:142, 06:107, <b>B*07:55, B*07:100, B*15:45, B*15:63, B*15:248, B*15:287</b>
	215 bp		*02:60	<b>B*07:55, B*07:100, B*08:70, B*15:07:01-15:07:03, B*15:45, B*15:68, B*15:126, B*15:207, B*46:12, B*48:19</b>
<b>26</b>	140 bp	1070 bp	*02:39-02:40, 02:53	
<b>27</b>	140 bp	<b>800 bp</b>	*02:44-02:45, 02:53	
<b>28<sup>5,8</sup></b>	90 bp	<b>800 bp</b>	*02:52N	*06:81, <b>B*07:55, B*07:100, B*08:70, B*15:07:01-15:07:03, B*15:45, B*15:68, B*15:126, B*15:207, B*46:12, B*48:19</b>
	210 bp		*02:37, 02:46, 02:60, 02:67Q	

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: <b>99V</b>		Lot-specific information		
<b>29</b>	210 bp	1070 bp	*02:12, 02:49, 02:55	*04:03:01, 04:06, 04:80, 04:107, 04:147, 04:160
<b>30</b> <sup>5,7</sup>	80 bp 270 bp	1070 bp	*02:38N *02:58	*01:35, 04:08, 04:34, 04:147, 05:27, 05:39, 06:96, 08:41, 12:83, 12:106, 12:122, 14:20, 15:15, 15:77, 17:07
<b>31</b> <sup>5</sup>	100 bp	1070 bp	*02:42	*01:21, 04:140, 04:166, 05:98, 06:05, 07:02:09, 08:14, 08:80, 08:103, 12:16, 15:63, <b>B*67:02</b>
<b>32</b> <sup>9</sup>	<b>Negative Control</b>			

<sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-C\*02 high resolution SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>For several HLA Class I alleles 1<sup>st</sup> and/or 4<sup>th</sup> exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

<sup>4</sup>Due to the sharing of sequence motifs between HLA-C alleles, non-HLA-C\*02 alleles will be amplified by primer mixes 1 to 8, 10, 12 to 14, 16 to 18, 20 to 22, 24, 25, 28 to 30 and 31. In addition, a few HLA-A and HLA-B alleles will be amplified by primer mixes 3 to 5, 12, 16, 19, 20, 22, 25, 28 and 31.

<sup>5</sup>HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

<sup>6</sup>Primer mixes 13 and 16 may give a lower yield of HLA-specific PCR product than the other C\*02 primer mixes.

<sup>7</sup>Primer mixes 10, 16 and 30 may have tendencies of unspecific amplifications.

<sup>8</sup>The C\*07 alleles might be faintly amplified by primer mix 28.

<sup>9</sup>Primer mix 32 contains a negative control, which will amplify more than 95% of HLA amplicons as well as the amplicons generated by control primer pairs. PCR product sizes range from 75 to 200 base pairs. The PCR product generated by the control primer pair is 430 base pairs.

‘w’, might be weakly amplified.

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
"Instructions for Use" (IFU)

Lot No.: **99V**

Lot-specific information  
**PRIMER SPECIFICATION**

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec. PCR product	250	95	100	65	145	160	130	70	200	130	90	150
			135	150	240	210		280			170	230
Length of int. pos. control <sup>1</sup>	800	800	800	1070	1070	800	800	1070	1070	1070	800	1070
5'-primer(s) <sup>2</sup>	2 <sup>nd</sup> I	486	486	92	361	364	2 <sup>nd</sup> I	105	703	113	486	97
	5'-CCA 3'	5'-ACA 3'	5'-ACA 3'	5'-gTg 3'	5'-AgT 3'	5'-ggT 3'	5'-CCA 3'	5'-gCT 3'	5'-CTA 3'	5'-CCA 3'	5'-ACA 3'	5'-TCg 3'
				463	453	370				118		368
				5'-TgA 3'	5'-AAT 3'	5'-ACT 3'				5'-CCA 3'		5'-gTT 3'
						420						449
						5'-TTA 3'						5'-CCA 3'
3'-primer(s) <sup>3</sup>	538	538	538	201	559	538	418	134	861	201	527	201
	5'-CCA 3'	5'-CCA 3'	5'-CAg 3'	5'-CTT 3'	5'-CTC 3'	5'-CCA 3'	5'-gTC 3'	5'-AgC 3'	5'-TCg 3'	5'-CTT 3'	5'-CCg 3'	5'-CTT 3'
			555	486				343			538	559
			5'-CCg 3'	5'-gCT 3'				5'-g 3'			5'-CCg 3'	5'-CTC 3'
			578								613	
			5'-TgT 3'								5'-gCA 3'	
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Length of spec. PCR product	225	80	130	250	110	235	80	50	115	65	85	325
	265	115	190		160			180	210	110	210	
								215			390	
Length of int. pos. control <sup>1</sup>	1070	800	1070	1070	1070	800	1070	1070	1070	1070	1070	1070
5'-primer(s) <sup>2</sup>	118	486	113	2 <sup>nd</sup> I	486	118	486	302	125	244	322	409
	5'-CCA 3'	5'-ACA 3'	5'-CCA 3'	5'-CCA 3'	5'-ACA 3'	5'-CCg 3'	5'-ACA 3'	5'-gAA 3'	5'-CgA 3'	5'-CgC 3'	5'-gCC 3'	5'-ggC 3'
			369			118		369	370	463	703	
			5'-TAC 3'			5'-CCg 3'		5'-TAC 3'	5'-ACT 3'	5'-TgA 3'	5'-CTA 3'	
								373				
								5'-gCg 3'				
								374				
								5'-CTA 3'				
3'-primer(s) <sup>3</sup>	302	527	201	538	555	312	527	312	201	312	419	3 <sup>rd</sup> I
	5'-ggC 3'	5'-CCg 3'	5'-CTT 3'	5'-CAg 3'	5'-CCg 3'	5'-AgT 3'	5'-CCA 3'	5'-Agg 3'	5'-CTT 3'	5'-AgT 3'	5'-Cgg 3'	5'-CTC 3'
	302	559	515		559			506	538	486	745	
	5'-ggC 3'	5'-CgT 3'	5'-CCA 3'		5'-CgT 3'			5'-Tgg 3'	5'-CCA 3'	5'-gCT 3'	5'-AgC 3'	
	341		518		603			515			865	
	5'-CgT 3'		5'-CCA 3'		5'-TTg 3'			5'-CCA 3'			5'-CCT 3'	
								545			871	
								5'-AgA 3'			5'-CgA 3'	
Well No.	13	14	15	16	17	18	19	20	21	22	23	24

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **99V**

Lot-specific information

Well No.	25	26	27	28	29	30	31
Length of spec.	160	140	140	90	210	80	100
PCR product	215			210		270	
Length of int. pos. control <sup>1</sup>	<b>800</b>	1070	<b>800</b>	<b>800</b>	1070	1070	1070
5'-primer(s) <sup>2</sup>	363	105	105	105	118	2 <sup>nd</sup> I	142
	5'-AgC 3'	5'-gCT 3'	5'-gCT 3'	5'-gCT 3'	5'-CCA 3'	5'-CCA 3'	5'-TCT 3'
	419	486	486	359			
	5'-gTA 3'	5'-ACA 3'	5'-ACA 3'	5'-CCg 3'			
				363			
				5'-AgC 3'			
				364			
				5'-ggT 3'			
				373			
				5'-gCg 3'			
3'-primer(s) <sup>3</sup>	538	203	202	153	289	369	201
	5'-CCA 3'	5'-CTg 3'	5'-TCC 3'	5'-ACT 3'	5'-AgC 3'	5'-CCT 3'	5'-CTT 3'
		580	578	538	289	558	
		5'-TCC 3'	5'-TgA 3'	5'-CCA 3'	5'-AgC 3'	5'-Agg 3'	
		595	595				
		5'-CCT 3'	5'-CCT 3'				
Well No.	25	26	27	28	29	30	31

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>2</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **99V**

Lot-specific information

CELL LINE VALIDATION SHEET					Well																
HLA-C*02 SSP primer set <sup>2</sup>					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
					Prod. No.:	201071901	201071902	201071903	201437704	201071905	201437706	201071907	201071908	201071909	201071910	201071911	201071912	201437713	201184414	201437715	201071916
IHCW cell line <sup>1</sup>			C*																		
1	9001	SA	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280	LK707	*07:01	*15:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
3	9011	E4181324	*12:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
4	9275	GU373	*03:04	*04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
5	9009	KAS011	*06:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
6	9353	SM	*03:04	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
7	9020	QBL	*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	9025	DEU	*04:01		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
9	9026	YAR	*12:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
10	9107	LKT3	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051	PITOUT	*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
12	9052	DBB	*06:02		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	9004	JESTHOM	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071	OLGA	*01:02	*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
15	9075	DKB	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037	SWEIG007	*02:02		+	+	-	-	-	-	-	-	+	+	-	-	-	-	-	-	
17	9282	CTM3953540	*03:03	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
18	9257	32367	*01:02	*07:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
19	9038	BM16	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059	SLE005	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064	AMALA	*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
22	9056	KOSE	*12:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
23	9124	IHL	*01:02	*15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
24	9035	JBUSH	*12:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
25	9049	IBW9	*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
26	9285	WT49	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191	CH1007	*07:04	*15:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
28	9320	BEL5GB	*05:01	*16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
29	9050	MOU	*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
30	9021	RSH	*17:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
31	9019	DJCAF	*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
32	9297	HAG	*17:01	*17:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
33	9098	MT14B	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
34	9104	DHIF	*12:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
35	9302	SSTO	*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	9024	KT17	*03:03	*04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
37	9065	HHKB	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	9099	LZL	*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
39	9315	CML	*02:02	*07:01	+	+	-	-	-	-	-	-	+	+	-	-	-	-	-	-	
40	9134	WHONP199	*01:02	*06:02	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
41	9055	H0301	*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	9066	TAB089	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076	T7526	*01:02	*08:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
44	9057	TEM	*12:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
45	9239	SHJO	*06:02	*17:01	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
46	9013	SCHU	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
47	9045	TUBO	*07:04	*15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
48	9303	TER-ND	*04:01	*16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **99V**

Lot-specific information

CELL LINE VALIDATION SHEET																					
HLA-C*02 SSP primer set <sup>2</sup>																					
				Well																	
				17	18	19	20	21	22	23	24	25	26	27	28	29	30	31			
				Prod. No.:	201184417	201201618	201201619	201437720	201437721	201437722	201437723	201071924	201437725	201437726	201437727	201437728	201184429	201437730	201184431		
IHC cell line <sup>1</sup>		C*																			
1	9001 SA	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
2	9280 LK707	*07:01	*15:05	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
3	9011 E4181324	*12:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
4	9275 GU373	*03:04	*04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
5	9009 KAS011	*06:02		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
6	9353 SM	*03:04	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
7	9020 QBL	*05:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
8	9007 DEM	*04:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
9	9026 YAR	*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
10	9107 LKT3	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
11	9051 PITOUT	*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
12	9052 DBB	*06:02		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
13	9004 JESTHOM	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
14	9071 OLGA	*01:02	*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
15	9075 DKB	*03:04		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
16	9037 SWEIG007	*02:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
17	9282 CTM3953540	*03:03	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
18	9257 32367	*01:02	*07:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
19	9038 BM16	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
20	9059 SLE005	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
21	9064 AMALA	*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
22	9056 KOSE	*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
23	9124 IHL	*01:02	*15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
24	9035 JBUSH	*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
25	9049 IBW9	*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
26	9285 WT49	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
27	9191 CH1007	*07:04	*15:05	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
28	9320 BEL5GB	*05:01	*16:01	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
29	9050 MOU	*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
30	9021 RSH	*17:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
31	9019 DUCAF	*05:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
32	9297 HAG	*17:01	*17:03	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
33	9098 MT14B	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
34	9104 DHIF	*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
35	9302 SSTO	*05:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
36	9024 KT17	*03:03	*04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
37	9065 HHKB	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
38	9099 LZL	*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
39	9315 CML	*02:02	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
40	9134 WHONP199	*01:02	*06:02	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
41	9055 H0301	*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
42	9066 TAB089	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
43	9076 T7526	*01:02	*08:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
44	9057 TEM	*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
45	9239 SHJO	*06:02	*17:01	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
46	9013 SCHU	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
47	9045 TUBO	*07:04	*15:02	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
48	9303 TER-ND	*04:01	*16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		

<sup>1</sup>The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

**Lot No.: 99V**

**Lot-specific information**

<sup>2</sup>The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 3 to 8, 11, 12, 14, 15, 17, 19 to 23, 26, 27, 30 and 31 were available. The specificity of the primers in primer solutions 3 to 8, 11, 12, 14, 15, 17, 19, 20, 22, 23, 26, 30 and 31 were tested by separately adding one additional 5'-primer, respectively one additional 3'-primer. In primer solution 21 it was only possible to test the 3'-primer, the 5'-primer was not possible to test. In primer solution 27 it was only possible to test the 5'-primer, the 3'-primer was not possible to test. In primer solutions 3, 8, 11, 13, 15, 17, 20, 23, 26, 28 and 30 one, two or three of the 3'-primers were not possible to test, and in primer solutions 4, 6, 10, 12, 15, 22, 23 and 28 one, two or three 5'-primers were not possible to test.

Additional primers in primer solutions 13, 25 and 28 were tested by separately adding either one 5'-primer, one or two 3'-primers.

101.622-12 - including *Taq* pol., IFU-01  
101.622-12u - without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **99V**

Lot-specific information

**ADDRESSES:**

**Manufacturer:**

**Olerup SSP AB**, Franzengatan 5, SE-112 51 Stockholm, Sweden.

**Tel:** +46-8-717 88 27

**Fax:** +46-8-717 88 18

**E-mail:** [info-ssp@olerup.com](mailto:info-ssp@olerup.com)

**Web page:** <http://www.olerup-ssp.com>

**Distributed by:**

**Olerup GmbH**, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

**Tel:** +43-1-710 15 00

**Fax:** +43-1-710 15 00 10

**E-mail:** [support-at@olerup.com](mailto:support-at@olerup.com)

**Web page:** <http://www.olerup.com>

**Olerup Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-OLERUP1

**Fax:** 610-344-7989

**E-mail:** [info.us@olerup.com](mailto:info.us@olerup.com)

**Web page:** <http://www.olerup.com>

For information on *Olerup* SSP distributors worldwide, contact **Olerup GmbH**.